June 2 Quick Takes: Genmab, Bolt get bispecific; plus AbbVie, Transine, Sanofi, Puyi
Genmab A/S (NASDAQ:GMAB; CSE:GMAB) and Bolt Biotherapeutics Inc. (NASDAQ:BOLT) partnered to discover and develop bispecific immune-stimulating antibody conjugates using Genmab’s antibodies and bispecific antibody technologies with Bolt’s Boltbody immune-stimulating antibody conjugate technology. Genmab has an option to develop and commercialize up to three compounds, with Bolt having an option to participate in development and commercialization of one therapy. Bolt will receive $10 million up front and a $15 million equity investment from Genmab and is eligible for $285 million in milestones, plus tiered royalties.
Positive top-line Phase III results in a maintenance study of Skyrizi risankizumab from AbbVie Inc. (NYSE:ABBV) have moved the therapy a step closer to building out its label with additional indications. Approved for psoriasis, the blockbuster, which is an inhibitor of the p19 subunit of IL-23, met the co-primary endpoints of endoscopic response and clinical remission at one year in adults with moderate-to-severe Crohn's disease. Skyrizi already met the primary endpoints in two Phase III studies as induction therapy in Crohn’s...